FDA
approval
· 2016-09-20
FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
Summary
FDA approved a supplemental application for the fixed-dose combination irbesartan and hydrochlorothiazide (Teva). The product is used to treat hypertension.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)